Specialist AI Team from "PersonalAIze" Highlights the Strength, Potential and Visionary Talent Behind Software as a Service (SaaS) Platform for Early Cancer Detection: Renovaro, Inc. (Nasdaq: RENB)

Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.

RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.

Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: "We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze's expertise."

Frank van Asch remarked on the collaboration, "The expertise of PersonalAIze's team is exceptional, and their positive evaluation of our AI/ML platform is invaluable."

The RENB RenovaroCube AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.

The initial aim for RENB is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.

In their analysis, PersonalAIze noted the RENB platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform's unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch's leadership.

Based on these findings, PersonalAIze is eager to collaborate further with RENB RenovaroCube to enhance and commercialize the platform.

PersonalAIze aims to contribute in several key areas:

Advancing AI models by leveraging the latest state-of-the-art techniques.

Enhancing the explainability of AI models, engaging clinicians in model development.

Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.

This partnership for RENB could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.

RENB RenovaroCube Presented Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

RENB has presented two scientific presentations at a leading cancer conference - the European Society for Medical Oncology (ESMO) Congress - on September 15, 2024.

One RENB presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube's current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.

A second RENB study demonstrated the Cube platform's ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.

To Review $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/

Disclaimer and Disclosure: www.aibrandnetwork.com
Media Contact
Company Name: Renovaro Biosciences Inc
Contact Person: The Hon. Mark Dybul, MD, CEO
Email: Send Email [http://www.universalpressrelease.com/?pr=specialist-ai-team-from-personalaize-highlights-the-strength-potential-and-visionary-talent-behind-software-as-a-service-saas-platform-for-early-cancer-detection-renovaro-inc-nasdaq-renb]
Phone: 732-780-5036
Address:2080 Century Park East Suite 906
City: Los Angeles
State: California 90067
Country: United States
Website: https://www.enochianbio.com/overview/default.aspx



This release was published on openPR.